South & Central America Stem Cell Therapy Market Forecast to 2028 - Regional Analysis - by Type, Treatment, Application, and End User

The South & Central America stem cell therapy is expected to grow from US$ 75.16 million in 2022 to US$ 139.30 million by 2028. It is estimated to grow at a CAGR of 10.8% from 2022 to 2028.

Use of Induced Pluripotent Stem Cells in Regenerative Medicines Drives South & Central America Stem Cell Therapy Market

Per the Frontiers Media S.A. 2023 report, progress in the field of induced pluripotent stem cells (iPSCs) has opened a new gateway for research in therapeutics. iPSCs are mainly intended for research and clinical studies such as disease modeling, regenerative medicine, and drug discovery/drug cytotoxicity studies. For example, iPSCs can be used to convert differentiated somatic cells to multipotent stem cells to generate different cell types of adult tissues. Thus, iPSCs have shown promising results in regenerative medicine, particularly for replacing diseased or injured cells. iPSCs are widely used to regenerate tissue-specific cells for transplantation in patients for treating injuries and degenerative diseases. Studies such as drug discovery involving screening of small molecules and toxicity testing for safety assessment have been successfully disclosed positive iPSCs-based results. The aforementioned factors are expected to offer lucrative growth opportunities to companies in the South & Central America stem cell therapy market in the coming years.

South & Central America Stem Cell Therapy Overview

The government and healthcare authorities in Brazil are implementing constructive strategies to increase the awareness and exposure of stem cell therapies in the countries. For example, providing international exposure, the authorities are focusing on conducting clinical trials in the country. For instance, according to clinicaltrials.gov, in 2016, around 27 stem cell studies were being conducted in the country, which accounted for an estimated 1.7% of all the stem cell studies across the globe. Also, the country allotted around US$ 5.0 Mn for stem cell research at the starting beginning of the entry in the stem cell domain. Increasing awareness in the country is fueling the growth of innovations and discoveries in the stem cell market. For instance, in 2017, R-Crio, a Brazil-based startup, discovered a way to produce around 7 million stem cells from a single baby tooth. These factors are likely to drive the growth of the Brazil stem cell therapy market during the forecast period.

South & Central America Stem Cell Therapy Revenue and Forecast to 2028 (US$ Million)

South & Central America Stem Cell Therapy Segmentation

The South & Central America stem cell therapy is segmented into type, treatment, application, end user, and country.

Based on type, the South & Central America stem cell therapy is segmented into adult stem cell therapy, embryonic stem cell therapy, induced pluripotent stem cell therapy, and other stem cell therapy. In 2022, the adult stem cell therapy segment registered the largest share in the South & Central America stem cell therapy. The adult stem cell therapy segments is further segmented into hematopoietic stem cell therapy, umbilical cord stem cell therapy, neuronal stem cell therapy, and mesenchymal stem cell.

Based on treatment, the South & Central America stem cell therapy is bifurcated into allogeneic and autologous. In 2022, the allogeneic segment registered a larger share in the South & Central America stem cell therapy.

Based on application, the South & Central America stem cell therapy is segmented into musculoskeletal, dermatology, cardiology, drug discovery & development, and other applications. In 2022, the musculoskeletal segment registered the largest share in the South & Central America stem cell therapy.

Based on end user, the South & Central America stem cell therapy is bifurcated into hospitals & specialty clinics and academic & research institutes. In 2022, the academic & research institutes segment registered a larger share in the South & Central America stem cell therapy.

Based on country, the South & Central America stem cell therapy is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2022, Brazil segment registered the largest share in the South & Central America stem cell therapy.

Lonza Group AG, Pluri Inc, Smith & Nephew Plc, and TiGenix NV (Takeda Pharmaceutical Company Limited) are some of the leading companies operating in the South & Central America stem cell therapy.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America stem cell therapy market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the South & Central America stem cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the stem cell therapy market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution